Mitral Valve Insufficiency

Categories: Cardiovascular diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Mitral Valve Insufficiency

MalaCards integrated aliases for Mitral Valve Insufficiency:

Name: Mitral Valve Insufficiency 11 43 14 71 33
Mitral Regurgitation 11 28 53 5 14 75
Congenital Insufficiency of Mitral Valve 11 71 33
Congenital Mitral Insufficiency 11 31 33
Congenital Mitral Regurgitation 11 33
Mitral Valve Incompetence 11 33
Congenital Mitral Valve Insufficiency 33
Congenital Mitral Valve Regurgitation 33
Congenital Mitral Valve Incompetence 33
Mitral Valve Annular Incompetency 33
Congenital Mitral Incompetence 33
Mr - [mitral Regurgitation] 33
Mitral Valve Regurgitation 33
Mi - [mitral Incompetence] 33


External Ids:

Disease Ontology 11 DOID:11502
ICD9CM 34 396.3 746.6
MeSH 43 D008944
NCIt 49 C50888
ICD10 31 Q23.3
UMLS 71 C0026266 C0158619 C0264774

Summaries for Mitral Valve Insufficiency

MalaCards based summary: Mitral Valve Insufficiency, also known as mitral regurgitation, is related to pulmonary hypertension and angina pectoris. An important gene associated with Mitral Valve Insufficiency is TBX5 (T-Box Transcription Factor 5), and among its related pathways/superpathways are Cardiac conduction and Embryonic and Induced Pluripotent Stem Cells and Lineage-specific Markers. The drugs Ranolazine and Angiotensin II have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and whole blood, and related phenotypes are muscle and homeostasis/metabolism

Wikipedia: 75 Mitral regurgitation (MR), also known as mitral insufficiency or mitral incompetence, is a form of... more...

Related Diseases for Mitral Valve Insufficiency

Diseases in the Mitral Valve Disease family:

Mitral Valve Insufficiency

Diseases related to Mitral Valve Insufficiency via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 774)
# Related Disease Score Top Affiliating Genes
1 pulmonary hypertension 31.6 REN NPPB NPPA CRP ACE
2 angina pectoris 31.2 TNNI3 NPPB CRP ACE
3 rheumatic fever 31.2 NPPB ALB ACE
4 third-degree atrioventricular block 31.1 TNNI3 NPPB CRP ACE
5 cardiomyopathy, familial hypertrophic, 1 31.1 TNNT2 TNNT1 TNNI3 MYH6 MYH11 MYBPC3
6 coronary stenosis 31.1 TNNI3 NPPB CRP ACE
7 atrial fibrillation 31.1 TNNI3 TBX5 NR3C2 NPPB NPPA F2
8 cardiogenic shock 31.1 NPPB NPPA
9 libman-sacks endocarditis 31.0 F2 CRP
10 inferior myocardial infarction 31.0 TNNT2 TNNT1 TNNI3 NPPB ACE
11 amyloidosis 30.9 NPPB MME CRP ALB
12 cardiac sarcoidosis 30.9 NPPB CRP ACE
13 postural orthostatic tachycardia syndrome 30.9 REN FBN1 CRP
14 cardiac arrest 30.8 TNNT2 TNNI3 NPPB CRP ACE
15 transposition of the great arteries, dextro-looped 30.8 TBX5 NPPB MIR423
16 infective endocarditis 30.8 NPPB F2 CRP ALB ACE
17 atrioventricular block 30.8 TNNT2 TNNI3 TBX5 NPPB MYH6 CRP
18 endocarditis 30.8 TNNT2 TNNI3 F2 CRP ALB
19 pericarditis 30.8 TNNT2 TNNI3 NPPB CRP ACE
20 acute kidney failure 30.7 REN NPPA F2 ALB ACE
21 lipid metabolism disorder 30.6 REN CRP ALB ACE
22 sick sinus syndrome 30.6 NPPA MYH6 F2
23 congenitally corrected transposition of the great arteries 30.6 TNNT2 NPPB
24 hyperthyroidism 30.6 REN F2 CRP ALB
25 ventricular septal defect 30.6 TNNT2 TBX5 NPPB NPPA MYH6 MIR423
26 left bundle branch hemiblock 30.6 TNNT2 TNNT1 TNNI3 REN NR3C2 NPPB
27 nonbacterial thrombotic endocarditis 30.5 F2 CRP
28 peripheral vascular disease 30.5 REN F2 CRP ALB ACE
29 anomalous left coronary artery from the pulmonary artery 30.5 NPPB ACE
30 cerebrovascular disease 30.5 REN MIR423 F2 CRP ALB ACE
31 rheumatic myocarditis 30.5 TNNT2 TNNI3 CRP
32 mitral valve stenosis 30.5 REN NR3C2 NPPB NPPA F2 CRP
33 pulmonary valve insufficiency 30.5 REN NPPB FBN1 CRP ACE
34 pulmonary disease, chronic obstructive 30.5 NPPB CRP ALB ACE
35 behcet syndrome 30.5 F2 CRP ALB ACE
36 transient cerebral ischemia 30.5 REN NPPB F2 CRP ALB ACE
37 amyloidosis, hereditary, transthyretin-related 30.5 TNNT2 NPPB MYBPC3 ALB
38 aortic aneurysm 30.5 REN MYH11 FBN1 F2 CRP ALB
39 aortic valve disease 1 30.4 TBX5 REN NPPB MYH6 MYH11 MIR423
40 myocardial stunning 30.4 TNNT2 TNNT1 TNNI3 NPPB ACE
41 wolff-parkinson-white syndrome 30.4 TNNT2 TBX5 NPPB MYH6 MYBPC3
42 anterolateral myocardial infarction 30.4 NPPB NPPA ACE
43 aortic aneurysm, familial thoracic 1 30.4 REN NDE1 MYH6 MYH11 FBN1 CRP
44 cardiac tamponade 30.4 TNNI3 REN NPPB F2 CRP ALB
45 heart septal defect 30.4 TNNT2 TBX5 NPPB NPPA MYH6 MIR423
46 nutritional deficiency disease 30.4 F2 CRP ALB
47 aortic valve insufficiency 30.4 TNNI3 REN NPPB MYH11 FBN1 F2
48 left ventricular noncompaction 30.4 TNNT2 TNNI3 TBX5 MYH6 MYBPC3 FBN1
49 aortic aneurysm, familial abdominal, 1 30.3 REN MYH11 FBN1 CRP ALB ACE
50 glomerulonephritis 30.3 REN CRP ALB ACE

Graphical network of the top 20 diseases related to Mitral Valve Insufficiency:

Diseases related to Mitral Valve Insufficiency

Symptoms & Phenotypes for Mitral Valve Insufficiency

MGI Mouse Phenotypes related to Mitral Valve Insufficiency:

# Description MGI Source Accession Score Top Affiliating Genes
1 muscle MP:0005369 10 ALB F2 FBN1 MYBPC3 MYH11 MYH6
2 homeostasis/metabolism MP:0005376 9.8 ACE ALB CRP F2 FBN1 MME
3 cardiovascular system MP:0005385 9.5 ACE ALB CRP F2 FBN1 MYBPC3

Drugs & Therapeutics for Mitral Valve Insufficiency

Drugs for Mitral Valve Insufficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 106)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
Candesartan cilexetil Approved Phase 4 145040-37-5
Tetracosactide Approved Phase 4 16960-16-0 16133802 16129617
Etomidate Approved Phase 4 33125-97-2 667484
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
Hydralazine Approved Phase 4 86-54-4 3637
Candesartan Experimental Phase 4 139481-59-7 2541
protease inhibitors Phase 4
14 HIV Protease Inhibitors Phase 4
15 Diuretics, Potassium Sparing Phase 4
16 Sodium Channel Blockers Phase 4
17 Serine Proteinase Inhibitors Phase 4
18 Antithrombins Phase 4
19 Antithrombin III Phase 4
20 Anticoagulants Phase 4
21 Antioxidants Phase 4
22 Omega 3 Fatty Acid Phase 4
Angiotensinogen Phase 4 16133225
24 Angiotensin II Type 1 Receptor Blockers Phase 4
25 Giapreza Phase 4
26 Vasoconstrictor Agents Phase 4
27 Hormones Phase 4
28 Hormone Antagonists Phase 4
29 Anti-Inflammatory Agents Phase 4
30 Anesthetics, Intravenous Phase 4
31 Anesthetics, General Phase 4
32 Hydrocortisone 17-butyrate 21-propionate Phase 4
33 Hypnotics and Sedatives Phase 4
34 Sacubitril and valsartan sodium hydrate drug combination Phase 4
35 Mineralocorticoids Phase 4
36 Mineralocorticoid Receptor Antagonists Phase 4
37 Anesthetics Phase 4
Serine Investigational, Nutraceutical Phase 4 56-45-1 5951
Metoprolol Approved, Investigational Phase 2, Phase 3 37350-58-6, 51384-51-1 4171
Bupivacaine Approved, Investigational Phase 3 2180-92-9, 38396-39-3 2474
Milrinone Approved Phase 3 78415-72-2 4197
Ertugliflozin Approved, Investigational Phase 3 1210344-57-2 75075340 44814423
Enalaprilat Approved Phase 3 76420-72-9 6917719 5462501
Enalapril Approved, Vet_approved Phase 3 75847-73-3 40466924 5388962 5362032
Nifedipine Approved Phase 3 21829-25-4 4485
46 Adrenergic beta-Antagonists Phase 2, Phase 3
47 Antihypertensive Agents Phase 2, Phase 3
48 Pharmaceutical Solutions Phase 3
49 Cardiotonic Agents Phase 3
50 Protective Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 326)
# Name Status NCT ID Phase Drugs
1 Interventional Strategy to Abrogate Mitral Regurgitation Using the MitraClip System in High-Risk Patients Considered Unsuitable for Surgery (ISAR-CLIP) Unknown status NCT01431222 Phase 4
2 Ranolazine Effects on Ischemic Mitral Regurgitation Severity in Patients With Cardiac Resynchronization Therapy Unknown status NCT01979965 Phase 4 Ranolazine (Active drug);Placebo
3 The Effect of Different Surgical Methods in the Treatment of Patients With Ischemic Mitral Regurgitation and Assess the Dynamics of Heart Failure and the Effectiveness of Surgical Treatment of Mitral Valve. Unknown status NCT01368575 Phase 4
4 (MitraClip in Non-Responders to Cardiac Resynchronization Therapy) Unknown status NCT02592889 Phase 4
5 Effects of the Administration Of Antithrombin on the Coagulation Status and on the Inflammatory Response in Patients With Low Plasmatic Levels of Antithrombin After Cardiac Surgery Unknown status NCT01201070 Phase 4 antithrombin III
6 Mitigating Cardiac Inflammation and Oxidative Stress in Atrial Myocardium Via Short-term Lovaza Treatment Prior to Surgery Unknown status NCT01046604 Phase 4 Lovaza group
7 Multicenter, Randomized, Double-blind, Active-controlled Study to Assess the Efficacy of LCZ696 Compared to Valsartan on Reduction of Mitral Regurgitation in Patients With Left Ventricular Dysfunction and Secondary Functional Mitral Regurgitation of Stage B and C Completed NCT02687932 Phase 4 LCZ696;Valsartan
8 Beta Blockade in Mitral Regurgitation Completed NCT00166400 Phase 4 metoprolol succinate
9 Angiotensin-II Blockade in Mitral Regurgitation Completed NCT00587470 Phase 4 Candesartan;atacand;Placebo
10 Colvin-Galloway Future® Annuloplasty Ring/Band Clinical Trial: Interventional Multi-center Prospective Clinical Outcome Study Completed NCT01074671 Phase 4
11 Study of Paravertebral Block for Cardiac Surgery Completed NCT02180893 Phase 4
12 Effect of an Anesthetic Induction Dose of Etomidate on Hemodynamics and Adrenocortical Function After Cardiac Surgery Completed NCT00415701 Phase 4 Etomidate;Propofol;Hydrocortisone;NaCl 0.9%
13 Clinical and Ultramicroscopic Myocardial Randomized Study of On-Pump Beating Heart Mitral Valve Replacement Completed NCT01641614 Phase 4
14 The Prognostic Impact of Using High-dose Hydralazine in Severe Systolic Heart Failure With Hemodynamically Significant Mitral Regurgitation Recruiting NCT04217135 Phase 4 evidence-based medications vs. high-dose hydralazine + evidence-based medications
15 Strategy To Optimize PeriproCeduraL AnticOagulation in Structural Transseptal Interventions Enrolling by invitation NCT05305612 Phase 4
16 High and Intermediate Risk Degenerative Mitral Regurgitation Treatment: A Randomized Controlled Trial Comparing MitraClip® to Surgical Therapy Terminated NCT02534155 Phase 4
17 Multicentre Randomized Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Severe Secondary Mitral Regurgitation. Unknown status NCT01920698 Phase 3
18 Randomized Evaluation of Mitral Annuloplasty During Coronary Artery Bypass Grafting for Moderate Functional Ischaemic Mitral Regurgitation. Completed NCT00413998 Phase 3
19 Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease) Completed NCT01052428 Phase 2, Phase 3 metoprolol succinate (Toprol XL);Placebo
20 Comparative Effects of Brief Inhaled Milrinone Versus Intravenous Milrinone on Pulmonary Arterial Pressure in Patients Undergoing Mitral Valve Surgery Completed NCT01621971 Phase 3 inhaled milrinone;intravenous milrinone
21 Clinical Investigation Of The Sorin 3D Annuloplasty Ring For Mitral Repair Completed NCT00567853 Phase 3
22 Postoperative Analgesia After Cardiac Surgery - A Double-Blind, Prospective and Randomized Comparison of Wound Infiltration With Liposomal Bupivacaine and Bupivacaine Hydrochloride Completed NCT03270514 Phase 3 Exparel Injectable Product;Bupivacaine Hydrochloride
23 Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy of Ertugliflozin on Reduction of Mitral Regurgitation in Patients With Functional Mitral Regurgitation Secondary to Left Ventricular Dysfunction Recruiting NCT04231331 Phase 3 Ertugliflozin;Placebo
24 The Safety and Effectiveness of the SAPIEN 3 and SAPIEN 3 Ultra Valve in Patients With Symptomatic Severe Calcific Mitral Valve Disease With Severe Mitral Annular Calcification Who Are Not Candidates for Standard Mitral Valve Surgery. Recruiting NCT04408430 Phase 2, Phase 3
25 Safety and Efficacy of Percutaneous Transvenous Mitral Annuloplasty System to Reduce Mitral Valve Regurgitation in Patients With Heart Failure Suspended NCT00815386 Phase 2, Phase 3
26 Trial of ACE Inhibition in Children With Mitral Regurgitation After Repair of AVSD Terminated NCT00113698 Phase 3 Enalapril
27 Surgery Versus Medical Treatment Alone for Patients With Significant Mitral Regurgitation and Non-ischemic Congestive Heart Failure: SMMART-HF Terminated NCT00608140 Phase 3 Optimal medical therapy (OMT)
28 Dynamic Annuloplasty System With Activation for the Treatment of Mitral Regurgitation Unknown status NCT00833014 Phase 2
29 Evaluation of Outcomes Following Mitral Valve Repair/Replacement in Severe Chronic Ischemic Mitral Regurgitation Completed NCT00807040 Phase 2
30 The Study for Atrial Functional Mitral Regurgitation Response In Mitral Loop Cerclage Annuloplasty (AFRICA Study): Multi-center, Open Label, Single Arm, Feasibility Test Completed NCT03453853 Phase 1, Phase 2
31 An Open-Label, Single-Arm Pilot Study of the Safety and Efficacy of the Percutaneous Transvenous Mitral Annuloplasty Device Used to Reduce Mitral Regurgitation Completed NCT00572091 Phase 1, Phase 2
32 Comparison of Erector Spinae Plane Block and Pecto-Intercostal Facial Plane Block For Enhanced Recovery After Sternotomy in Adult Cardiac Surgery Completed NCT05475561 Phase 2 Bupivacain
33 A Study of the Evalve Cardiovascular Valve Repair System Endovascular Valve Edge-to-Edge REpair STudy (EVEREST I). Completed NCT00209339 Phase 1, Phase 2
34 Surgical Ablation Versus No Surgical Ablation for Patients With Persistent or Longstanding Persistent Atrial Fibrillation (AF) Undergoing Mitral Valve Surgery Completed NCT00903370 Phase 2
35 Safety and Efficacy of TP10, a Complement Inhibitor, in Adult Women Undergoing Cardiopulmonary Bypass Surgery Completed NCT00082121 Phase 2 TP10
36 Randomized Evaluation of a Surgical Treatment for Off-Pump Repair of the Mitral Valve (RESTOR-MV) Completed NCT00120276 Phase 2
37 Evaluating the Severity of Mitral Regurgitation Using Phenylephrine During Transesophageal Echocardiography Recruiting NCT04500899 Phase 1, Phase 2 Mydfrin
38 Blocking the Effects of Serotonin to Prevent Ischemic Mitral Regurgitation: a Randomized Trial (CYPRO-MR) Not yet recruiting NCT05469165 Phase 2 Cyproheptadine 4 Mg Oral Tablet
39 A Multi-center Study of the Safety and Efficacy of the Percutaneous Transvenous Mitral Annuloplasty System to Reduce Mitral Valve Regurgitation in Patients With Heart Failure Suspended NCT00787293 Phase 2
40 V-Chordal Adjustable System for Chordal Replacement in Mitral Valve Insufficiency Due to Leaflet Prolapse Terminated NCT01415947 Phase 2
41 Mitral Valve Reconstruction in Patients With Chronic Heart Failure and Secondary Mitral Insufficiency: Identification of Predictors for a Successful Therapy Terminated NCT00348829 Phase 2
42 The RELIEF Trial: REduction or eLimination of mItral rEgurgitation in Degenerative or Functional Mitral Regurgitation With the CardiAQ-Edwards™ Transcatheter Mitral Valve Withdrawn NCT02722551 Phase 1, Phase 2
43 Medical Versus Surgical Management of Patients With Moderate Mitral Regurgitation Following Percutaneous Coronary Intervention for Myocardial Infarction: A Pilot Prospective Randomized Trial Withdrawn NCT01156441 Phase 1, Phase 2
44 Prospective.Randomized, Blinded, Crossover Chronic IDE Study of the Effects of Pacing on Mitral Regurgitation in Patients Without Standard Indications for Cardiac Resynchronization Therapy Unknown status NCT01242397 Phase 1
45 A Novel Adjustable Neochordae Technique in Mitral Valve Repair Unknown status NCT04299334 Phase 1
46 Valvular and Ventricular Improvement Via iCoapsys Delivery (VIVID) Feasibility Study Unknown status NCT00512005 Phase 1
47 An Open-Label, Single-Arm Feasibility Study of the Safety and Efficacy of the Percutaneous Transvenous Mitral Annuloplasty (PTMA) Device Used to Reduce Mitral Regurgitation. Completed NCT00568230 Phase 1
48 A Single-Center, Open-Label, Single-Arm Pilot Study of the Safety and Efficacy of the Percutaneous Transvenous Mitral Annuloplasty Implantable Device Used to Reduce Mitral Valve Regurgitation. Completed NCT00571610 Phase 1
49 TVMR With the Innovalve System Trial - Early Feasibility Study Not yet recruiting NCT04919980 Phase 1
50 Beta-Blockade in Chronic Mitral Regurgitation: Moving From the Laboratory Experiment to Clinical Investigation Terminated NCT00700947 Phase 1 Beta-blocker therapy (TOPROL-XL® )

Search NIH Clinical Center for Mitral Valve Insufficiency

Cochrane evidence based reviews: mitral valve insufficiency

Genetic Tests for Mitral Valve Insufficiency

Genetic tests related to Mitral Valve Insufficiency:

# Genetic test Affiliating Genes
1 Mitral Regurgitation 28

Anatomical Context for Mitral Valve Insufficiency

Organs/tissues related to Mitral Valve Insufficiency:

MalaCards : Heart, Brain, Whole Blood, Lymph Node, Atrioventricular Node, Kidney, Lung

Publications for Mitral Valve Insufficiency

Articles related to Mitral Valve Insufficiency:

(show top 50) (show all 18384)
# Title Authors PMID Year
A Screening Approach to Identify Clinically Actionable Variants Causing Congenital Heart Disease in Exome Data. 5
29555671 2018
Relationship between the tissue Doppler-derived Tei index and plasma brain natriuretic peptide levels in patients with mitral regurgitation. 53 62
20329488 2010
Comparison of clinical presentations and outcomes between patients with TGFBR2 and FBN1 mutations in Marfan syndrome and related disorders. 53 62
19996017 2009
Tei index correlates with tissue Doppler parameters and reflects neurohormonal activation in patients with an abnormal transmitral flow pattern. 53 62
19558518 2009
BNP in mitral valve restrictive annuloplasty for ischemic mitral regurgitation. 53 62
18657328 2009
Prospective validation of the prognostic usefulness of brain natriuretic peptide in asymptomatic patients with chronic severe mitral regurgitation. 53 62
19744620 2009
Decline of plasma brain natriuretic peptide during enzyme replacement therapy in a female patient with heterozygous Fabry's disease. 53 62
19282651 2009
Successful catheter ablation to accessory atrioventricular pathway as cardiac resynchronization therapy in a patient with dilated cardiomyopathy. 53 62
19028709 2009
Predictors of mortality from pump failure and sudden cardiac death in patients with systolic heart failure and left ventricular dyssynchrony: results of the CARE-HF trial. 53 62
18926439 2008
Dynamic left ventricular dyssynchrony contributes to B-type natriuretic peptide release during exercise in patients with systolic heart failure. 53 62
18319268 2008
Correlation of the myocardial performance index with plasma B-type natriuretic peptide levels in patients with mitral regurgitation. 53 62
17541723 2008
Elevated B-type natriuretic peptide despite normal left ventricular function on rest and exercise stress echocardiography in mitral regurgitation. 53 62
18202251 2008
The combination of B-type natriuretic peptide and C-reactive protein provides incremental prognostic value among older patients referred for cardiac catheterization. 53 62
17617749 2007
Assessment of factors affecting plasma BNP levels in patients with chronic atrial fibrillation and preserved left ventricular systolic function. 53 62
16959341 2007
Usefulness of the brain natriuretic peptide to atrial natriuretic peptide ratio in determining the severity of mitral regurgitation. 53 62
17380223 2007
Significance of brain natriuretic peptide in the evaluation of symptoms and the degree of left ventricular diastolic dysfunction in patients with hypertrophic cardiomyopathy. 53 62
17243506 2006
Association of B-type natriuretic peptide activation to left ventricular end-systolic remodeling in organic and functional mitral regurgitation. 53 62
16563910 2006
Predictors of remodeling in the CRT era: influence of mitral regurgitation, BNP, and gender. 53 62
16624682 2006
Efficacy of nasal bi-level positive airway pressure in congestive heart failure patients with cheyne-stokes respiration and central sleep apnea. 53 62
16041159 2005
Plasma BNP levels are determined by the severity of left ventricular systolic dysfunction but not the types of underlying heart disease. 53 62
15999470 2005
B-type natriuretic peptide in organic mitral regurgitation: determinants and impact on outcome. 53 62
15883225 2005
Clinical applications of B-type natriuretic peptide levels in the care of cardiovascular patients. 53 62
15729209 2004
Changes in type B natriuretic peptide (BNP) concentrations during cardiac valve replacement. 53 62
15144992 2004
Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. 53 62
15013124 2004
[Autoantibodies: new upstream targets of paroxysmal atrial fibrillation in patients with congestive heart failure]. 53 62
12463096 2002
Atrial natriuretic factor and mitral valve prolapse syndrome. 53 62
11533551 2001
Clinical correlates of elevated plasma natriuretic peptides and Big endothelin-1 in a population of ambulatory patients with heart failure. A substudy of the Italian Network on Congestive Heart Failure (IN-CHF) registry. IN-CHF Investigators. 53 62
10824729 2000
Acute mitral regurgitation due to chordal rupture in a patient with neonatal Marfan syndrome caused by a deletion in exon 29 of the FBN1 gene. 53 62
10441700 1999
Plasma atrial and brain natriuretic peptide levels in dogs with congestive heart failure. 53 62
10379945 1999
Hemodynamic correlates of atrial natriuretic peptide concentration in unselected patients with heart disease of different etiologies. 53 62
9887389 1998
Effect of continuous positive airway pressure on mitral regurgitant fraction and atrial natriuretic peptide in patients with heart failure. 53 62
9283534 1997
Associations between atrial natriuretic peptides, echocardiographic findings and mortality in an elderly population sample. 53 62
9159597 1997
Plasma atrial natriuretic peptide is elevated in patients with hypertrophic cardiomyopathy. 53 62
8842784 1996
Ventricular adenine nucleotide translocator mRNA is upregulated in dilated cardiomyopathy. 53 62
8252591 1993
A new and rare form of Williams' syndrome. 53 62
8351994 1993
[Correlations between plasma concentrations of atrial natriuretic factor and right ventricular function in patients with severe cardiac failure]. 53 62
1532302 1992
Dynamics of creatine kinase shuttle enzymes in the human heart. 53 62
1909638 1991
[Supravalvular aortic stenosis syndrome with advanced mitral regurgitation requiring extended aortoplasty and mitral valve replacement: a case report]. 53 62
2038171 1991
[Changes in PTCA. A model of ischemia in humans]. 53 62
1830715 1991
Estimation of Simulated Left Ventricle Elastance Using Lumped Parameter Modelling and Gradient-Based Optimization With Forward-Mode Automatic Differentiation Based on Synthetically Generated Noninvasive Data. 62
36082474 2023
Amlodipine decreases mitral regurgitation volume in dogs over 7 days: A study of 24 dogs with myxomatous mitral valve degeneration. 62
35414938 2022
Usefulness of computed tomography to predict residual mitral regurgitation after transcatheter mitral valve edge-to-edge repair. 62
35963710 2022
An autopsy case of sudden unexpected death with Barlow's disease. 62
35952984 2022
Mitral valve repair and tricuspid annuloplasty for Coffin-Lowry syndrome. 62
36069024 2022
Real-world clinical outcomes of percutaneous transluminal septal myocardial ablation for patients with drug-refractory hypertrophic obstructive cardiomyopathy: results from a retrospective multicenter registry of non-high-volume centers. 62
35641828 2022
Incidence and Predictors of New-Onset Atrial Fibrillation After Transcatheter Edge-to-Edge Repair of the Mitral Valve (from the Nationwide Readmissions Database). 62
36075754 2022
Artificial chordae for mitral valve repair. 62
36116053 2022
Mitral Annulus Geometry and Dynamic Motion Changes in Patients With Aortic Regurgitation: A Three-Dimensional Transesophageal Echocardiographic Study. 62
35811278 2022
Letter to the editor: "Papillary muscle intervention versus mitral ring annuloplasty in ischemic mitral regurgitation". 62
35916153 2022
Mitral Regurgitation and Mortality Risk in Medicare Beneficiaries With Heart Failure and Preserved Ejection Fraction. 62
36100504 2022

Variations for Mitral Valve Insufficiency

ClinVar genetic disease variations for Mitral Valve Insufficiency:

# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TBX5 NM_181486.4(TBX5):c.1221C>G (p.Tyr407Ter) SNV Pathogenic
495227 rs1555223259 GRCh37: 12:114793673-114793673
GRCh38: 12:114355868-114355868
2 overlap with 7 genes DEL Pathogenic
1684630 GRCh37: 17:8021110-8030264
GRCh38: 17:8117792-8126946
3 FBN1 NM_000138.5(FBN1):c.8016T>G (p.Cys2672Trp) SNV Likely Pathogenic
374081 rs1057518883 GRCh37: 15:48707768-48707768
GRCh38: 15:48415571-48415571
4 FBN1 NM_000138.5(FBN1):c.478T>C (p.Cys160Arg) SNV Likely Pathogenic
374203 rs1057518973 GRCh37: 15:48888540-48888540
GRCh38: 15:48596343-48596343
5 MYH11, NDE1 NM_002474.3(MYH11):c.4360G>C (p.Asp1454His) SNV Likely Pathogenic
374162 rs1057518938 GRCh37: 16:15818023-15818023
GRCh38: 16:15724166-15724166

Expression for Mitral Valve Insufficiency

Search GEO for disease gene expression data for Mitral Valve Insufficiency.

Pathways for Mitral Valve Insufficiency

Pathways related to Mitral Valve Insufficiency according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
Show member pathways
2 11.75 TNNT2 TNNI3 TBX5 ALB
Show member pathways
4 11.52 TNNT2 TNNI3 TBX5
Show member pathways
6 11.18 TNNT2 TNNI3 TBX5 MYH6
7 10.58 TBX5 NPPA

GO Terms for Mitral Valve Insufficiency

Cellular components related to Mitral Valve Insufficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sarcomere GO:0030017 9.76 TNNT2 TNNI3 MYH6 MYBPC3
2 myofibril GO:0030016 9.67 TNNT2 TNNI3 MYH6
3 myosin filament GO:0032982 9.65 MYH6 MYH11 MYBPC3
4 cardiac Troponin complex GO:1990584 9.62 TNNT2 TNNI3
5 troponin complex GO:0005861 9.43 TNNT2 TNNT1 TNNI3
6 cardiac myofibril GO:0097512 9.1 TNNT2 TNNI3 MYBPC3

Biological processes related to Mitral Valve Insufficiency according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 kidney development GO:0001822 10.05 REN MME FBN1 ACE
2 muscle contraction GO:0006936 10.01 MYH6 TNNI3 TNNT1 TNNT2
3 sarcomere organization GO:0045214 9.97 TNNT2 TNNT1 MYH6
4 blood vessel diameter maintenance GO:0097746 9.85 NPPB NPPA ACE
5 bradykinin catabolic process GO:0010815 9.83 MME ACE
6 hormone catabolic process GO:0042447 9.78 MME ACE
7 cardiac muscle contraction GO:0060048 9.76 MYBPC3 MYH6 TNNI3 TNNT2
8 substance P catabolic process GO:0010814 9.73 MME ACE
9 amyloid-beta metabolic process GO:0050435 9.73 REN MME ACE
10 regulation of blood pressure GO:0008217 9.65 REN NPPB NPPA MYH6 ACE
11 regulation of muscle contraction GO:0006937 9.5 TNNT2 TNNT1 TNNI3
12 regulation of system process GO:0044057 9.37 TNNT2 TNNT1
13 ventricular cardiac muscle tissue morphogenesis GO:0055010 9.23 TNNT2 TNNI3 MYH6 MYBPC3

Molecular functions related to Mitral Valve Insufficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone receptor binding GO:0051427 9.62 NPPB NPPA
2 exopeptidase activity GO:0008238 9.56 MME ACE
3 microfilament motor activity GO:0000146 9.55 TNNT2 MYH6 MYH11
4 troponin T binding GO:0031014 9.26 TNNT1 TNNI3
5 troponin C binding GO:0030172 8.92 TNNT2 TNNI3

Sources for Mitral Valve Insufficiency

8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
27 GO
28 GTR
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
36 LifeMap
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....